Christoph Broja
Direktor/Vorstandsmitglied bei Cardior Pharmaceuticals GmbH
Profil
Christoph Broja is a Managing Director in the EQT Life Sciences team since 2022.
Before joining EQT, he was a Principal in the investment team at Gurnet Point Capital based in Boston, where he was involved in a number of investments in biopharma, medical devices, and molecular diagnostics.
Prior to that, Christoph worked at B-Flexion Capital in London.
Christoph started his career as investment analyst at private equity firm Franz Haniel & Cie.
in Germany.
He holds a degree in Business Administration and is a CFA Charterholder.
Aktive Positionen von Christoph Broja
| Unternehmen | Position | Beginn |
|---|---|---|
| EQT Life Sciences (Munich) | Berater | 01.09.2022 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Direktor/Vorstandsmitglied | 01.09.2022 |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Private Equity Investor | 01.09.2022 |
Ehemalige bekannte Positionen von Christoph Broja
| Unternehmen | Position | Ende |
|---|---|---|
Gurnet Point Capital LLC
 Gurnet Point Capital LLC Investment ManagersFinance Gurnet Point Capital LLC (Gurnet Point Capital) is a private equity/venture capital firm founded in 2013 by Fereydoun Firouz. The firm is headquartered in Cambridge, Massachusetts. | Private-Equity-Analyst | 01.03.2021 |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Direktor/Vorstandsmitglied | 01.06.2022 |
Franz Haniel & Cie. GmbH
 Franz Haniel & Cie. GmbH Investment ManagersFinance Franz Haniel & Cie. GmbH is a Haniel family equity firm. The company was founded in 1756 by Jan Willem Noot and is headquartered in Duisburg, Germany. | Private-Equity-Analyst | 01.07.2012 |
Ausbildung von Christoph Broja
| Friedrich Schiller University of Jena | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
| EQT Life Sciences (Munich) | Finance |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Health Technology |
Gurnet Point Capital LLC
Gurnet Point Capital LLC Investment ManagersFinance Gurnet Point Capital LLC (Gurnet Point Capital) is a private equity/venture capital firm founded in 2013 by Fereydoun Firouz. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Tremeau Pharmaceuticals, Inc.
Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Health Technology |
Franz Haniel & Cie. GmbH
Franz Haniel & Cie. GmbH Investment ManagersFinance Franz Haniel & Cie. GmbH is a Haniel family equity firm. The company was founded in 1756 by Jan Willem Noot and is headquartered in Duisburg, Germany. | Finance |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Finance |
